Dr. Ashima Bhatia is a physician with an MD in Clinical Pharmacology from Delhi University.
She has more than 23 years’ experience in clinical development, clinical operations and medical affairs in industry and academia.
She has held positions of increasing responsibilities at Eli Lilly, Astra Zeneca, Pfizer and, Johnson & Johnson. She has worked in diverse therapeutic areas like Infectious diseases, cardiovascular, metabolic diseases, respiratory, oncology and critical care. She has worked on new product development strategies and designing and implementation of local and global registration studies from Phase I through IV.She has built and led high performing regional and global teams.
She joined Wockhardt in 2012 and is currently Chief Clinical Officer & Head for Global Clinical development and is responsible for clinical development of NCEs in the anti-infective space. She and her team have successfully filed 6 US INDs, got 2 NDA approvals and are currently running two Phase 3 trials – one in cUTI and the other in CABP. She and her team successfully completed phase I through phase III trials of an IV and an oral anti-MRSA drug, both of which were recently launched in India.
She has over 50 national and international publications to her credit and has presented at numerous conferences and symposia.